All In Biotech

Drug Trial Radar · NCT00799760

Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir

Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomises Double Blind Controlled Trial Study

Last checked: Nov 20, 2026Latest source record: Mar 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 541 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

541

Actual

Start

Dec 2008

Primary completion

Nov 2009

Study completion Nov 2010

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hoffmann-La Roche; GlaxoSmithKline
First posted
Dec 1, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir.The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2.

Conditions

  • Gastric Influenza

Interventions

  • oseltamivir + zanamivirDrug

    oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days

  • oseltamivir + zanamivir's placeboDrug

    oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day

  • oseltamivir's placebo + zanamivirDrug

    oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RT-PCR for influenza A virus in nasal secretionTime frame: 2 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Investigateur 155

    Deûlémont, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.